Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Sad news

<< Previous

Bullboard Posts

Next >>

Comment by juniper88on Jun 09, 2021 8:58am

143 Views

Post# 33353992

RE:RE:RE:Sad news

This came as a shock to me, especially when you consider one of the inclusion criteria of the trial:

"Have an expected survival of at least 3 months."

scarlet1967 wrote: Sad, my condolences to his family and love ones, it shows how desperately these grade 3 or 4 cancer patients need a treatment.

juniper88 wrote: My condolences to his family also. Sad news indeed.

jeffm34 wrote:
I think this might be TH's first patient in the cancer trial. Condolences to his family.

https://www.gettysburgtimes.com/obituaries/article_cb4e3798-3083-5062-9b44-9fd624857194.html